ASC secures additional funding to expand stem cell (iPSC) gene editing and its core gene insertion technology TARGATT™ | ASC

Milpitas, CA - February 10th, 2020: Applied StemCell, Inc. (ASC), a leading gene editing company, announced today its intention to focus and strategically expand its business following the divestment of its oncology products and cell line editing assets and technologies to Abcam. New R&D expansion focuses on two areas: development of iPSC-based products for research and therapeutic applications; and development of its proprietary TARGATT™ gene insertion technology. ASC continues to offer a wide range of gene editing in vitro for stem cell and CHO cells and in vivo for mouse and rat models, along with related products to support customers’ research and preclinical needs. In addition, ASC is pleased to announce the award of a new SBIR fast track award from the NIH .

New products in pipeline:

• iPSC allogeneic master lines
• iPSC differentiation technology and iPSC derived specific lineage cells
• Mammalian cell platform for high-throughput library screening (TARGATT modified HEK293 and CHO) 

Preclinical Services:

• CRISPR based genome editing in iPSC 
• CRISPR based genome editing in mouse, rat models 
• iPSC preclinical services (generation, characterization, expansion, and differentiation)
• TARGATT™ gene insertion platform (iPSC, HEK293, CHO)
• Humanized mouse models
• Mouse ESC derivation, characterization, and differentiation

Ruby Tsai, Co-Founder and CSO of Applied StemCell, commented: “It is our strategic decision to focus on further developing our core TARGATT gene insertion technology, stem cell and derivative service and products for both research and therapeutic applications. With the new grant from the NIH and sale of the oncology products and cell line editing assets to Abcam, we are ideally placed to continue to take our leading position in all aspect of stem cell gene editing offerings and drive our custom TARGATT™ services."

About TARGATT™

Applied StemCell’s proprietary TARGATT™ technology, enables site-specific, stable integration of large DNA fragments into a safe harbour locus more efficiently and faster, with guaranteed transgene expression. The TARGATT™ gene-editing platform is versatile and can generate large fragment knock-in animal or cell line models. This technology circumvents problems associated with random integration such as position effect, and gene silencing or instability due to integration of multiple copies of the transgene. Applications for TARGATT™ models: Transgene overexpression models, reporter gene knock-in, conditional knock-in, inducible expression, Cre-driver lines and humanized animal models.

About Applied StemCell, Inc.

Applied StemCell, Inc. is a fast-growing biotechnology company with more than 11 years of experience in genome editing and stem cell technologies. Our mission is to advance genome editing technology innovation to enable in vivo/in vitro preclinical study as well as develop more efficacious and safer gene and cell therapies.

More information can be found at www.appliedstemcell.com.